AustriaAustria

New study

09.03.2012

Breast cancer patients who receive radiation therapy often suffer from inflammation linked to the treatment. Austrian Apeiron Biologics AG is now developing a topical superoxide dismutase treatment (APN201) to try to help these women. The Viennese company has begun a further clinical trial at the University of Graz with 20 patients that have received radiation after breast surgery. APN201 was developed by Polymun Scientific AG, another biotech company based in Vienna. Apeiron in­licensed the compound, which has already completed several clinical trials, the most advanced in Phase II. The human enyzme superoxide dismutase is essential for protecting human cells from damage by reactive oxygen species that are created through radiation.

AustriaAustria

12.02.2010

Vienna – Austria-based Intercell AG yesterday announced that its first-in-man trial of the subunit vaccine IV47, designed to prevent infections from the majority of so Streptococcus pneumoniae serotypes, of which there are over...

AustriaAustria

01.02.2010

Vienna – Austrian-based biotech company f-star has closed an EUR8m extension to its Series A financing round. The investment was co-led by MP Healthcare Venture Management and Merck Serono Ventures. Existing investors Atlas...

AustriaAustria

01.02.2010

Vienna – With the naming of Beatrix Karl as the new Minister of Science, the Austrian government is complete. The 42 year-old legal scientist will follow pre­decessor Johannes Hahn, who has accepted a position as European...

AustriaAustria

01.02.2010

AustriaAustria

01.02.2010

Vienna – Austrian vaccine specialist Intercell and GlaxoSmithKline Biologicals SA (GSK) have formed a strategic alliance to commercialise needle-free, patch-based vaccines. The agreement will include Intercell’s candidate vaccine...

AustriaAustria

06.01.2010

Vienna – Austrian firm Intercell AG has initiated a phase II efficacy trial as part of its clinical development program for the investigational travellers’ diarrhoea (TD) vaccine in India. The primary objective of the field trial...

AustriaAustria

29.12.2009

Vienna – Austrian vaccine specialist Intercell AG is to expand the label of its vaccine Ixiaro/JEspect for Japanese encephalitis (JE). On Monday the company announced the start of a clinical phase III study for the travel...

Politics / Law, Miscellaneous, AustriaAustria

04.11.2009

Graz – Austria is likely to lead the EU’s efforts to integrate existing national biobanks and associated data throughout Europe into a European biobanking infrastructure. The resource is aimed at reaching critical mass for the...

AustriaAustria

21.09.2009

Vienna – Cardiovascular and inflammatory specialist Fibrex Medical has published positive Phase II results for FX06, a peptide for the treatment of reperfusion injury – damage to heart muscle that results from remedial treatment...

Politics / Law, AustriaAustria

14.07.2009

The cultivation of genetically modified organisms (GMOs) in the European Union could soon no longer be decided by scientific facts, but by political preferences. Fourteen member states – among them France, Poland and Portugal –...

Displaying results 31 to 40 out of 116

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/3/article/new-study.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.30 CHF6.45%
  • PAION3.17 EUR3.93%
  • SANTHERA90.75 CHF3.07%

FLOP

  • WILEX2.36 EUR-12.27%
  • THERAMETRICS0.08 CHF-11.11%
  • CYTOS0.23 CHF-4.17%

TOP

  • CO.DON3.27 EUR30.8%
  • PAION3.17 EUR27.8%
  • EPIGENOMICS3.80 EUR22.6%

FLOP

  • MEDIGENE3.82 EUR-17.8%
  • ADDEX3.30 CHF-17.5%
  • EVOTEC3.10 EUR-15.5%

TOP

  • SANTHERA90.75 CHF2124.3%
  • CO.DON3.27 EUR280.2%
  • PAION3.17 EUR213.9%

FLOP

  • CYTOS0.23 CHF-94.3%
  • THERAMETRICS0.08 CHF-42.9%
  • BIOFRONTERA2.18 EUR-40.3%

No liability assumed, Date: 21.09.2014


Current issue

All issues

Product of the week

Products